You are currently viewing archive.bio.org. Head to our home page to check out our fresh new look!

BIO Board of Directors

In accordance with its Bylaws and Articles of Incorporation, the Biotechnology Innovation Organization (BIO) is governed by its Board of Directors.  The Full BIO Board of Directors is comprised of all the directors sitting on the Section Governing Boards, as described below. 

In addition, there is a Board Executive Committee that consists of the seven Elected Officers of the Organization, the immediate Past Chair of the Organization, the Vice Chairs of each Section's Governing Board, and At-Large Directors selected from the Full Board.

There are four Section Governing Boards organized by industrial sector and policy interest.  They are: (1) the Emerging Companies Section (ECS) Governing Board, (2) the Food & Agriculture (F&A) Section Governing Board, (3) the Health Section Governing Board, and (4) the Industrial & Environmental (I&E) Section Governing Board.  BIO’s four Section Governing Boards are comprised of thought leaders who bring their expertise to bear on major issues affecting their specific area of the biotechnology industry.

From time to time, each Section Governing Board may consider candidates to fill vacancies in accordance with BIO’s Bylaws and their own processes and criteria.  In general, BIO Board candidates should be the CEO or Chairman of the Board of a research and development (R&D) focused biotechnology company, but certain Governing Boards have alternative criteria, especially for larger companies.  To be considered for a BIO Board seat, a candidate typically has this type of affiliation with a BIO member company.  If your organization is not a BIO member, click here to learn more about membership.

BECOME A BIO MEMBER

BIO is committed to fostering workforce development, diversity, and inclusion (WDDI) at BIO and across the biotechnology industry.  To that end, candidates should affirmatively support BIO’s WDDI Principles, and pledge to do her or his part to foster diversity and inclusion among employees, customers, and patients.  BIO’s WDDI Principles can be found at: https://www.bio.org/diversity

If you are interested in nominating yourself or another person to be a candidate and potentially fill a vacancy on the BIO Board, please inquire here to learn more about the BIO Board nomination process:

Inquire about BIO Board Nominations

If you have any questions about the BIO Board of Directors, please contact Peter McHugh at pmchugh@bio.org.

For reference, a diagram of the Board and Committee structure is presented below.

Board and Committee structure

 

Executive Committee

Executive Committee

Jeremy M. Levin, DPhil, MB BChir Board & Health Section Chair
Chairman & CEO, Ovid Therapeutics Inc.
John Maraganore, PhD Immediate Past Chair
Chief Executive Officer, Alnylam Pharmaceuticals, Inc.
Bradford A. Zakes, MBA Treasurer
President & Chief Executive Officer, Cerevast Therapeutics, Inc.
Julie L. Gerberding, MD, MPH Secretary
Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, Merck
Paul J. Hastings Health Section Vice Chair
President & CEO, Nkarta Therapeutics, Inc.
Ted W. Love, MD ECS Chair
Chief Executive Officer, Global Blood Therapeutics
John F. Crowley, JD, MBA ECS Vice Chair
Chairman & CEO, Amicus Therapeutics, Inc.
Philip W. Miller, PhD Food & Ag Section Chair
Sr. Vice President, Agricultural Global Government Relations, Regulatory Policy, Bayer CropScience, Inc.
Sylvia Wulf Food & Ag Section Vice Chair
Chief Executive Officer, AquaBounty Technologies, Inc.
Hugh Welsh, JD I&E Section Chair
General Counsel, Secretary & President, DSM North America
Jill Zullo, PhD I&E Section Vice Chair
Vice President, Bioindustrials NA, Cargill, Inc
Stuart A. Arbuckle
Executive Vice President and Chief Commercial Office, Vertex Pharmaceuticals Incorporated
Ron Cohen, MD
Founder, President & CEO, Acorda Therapeutics, Inc.
Douglas A. Doerfler
President & CEO, MaxCyte, Inc
Alexander Hardy
Chief Executive Officer, Genentech, A Member of the Roche Group
Rachel K. King
Founder & CEO, GlycoMimetics, Inc.
Richard Pops
Chairman & CEO, Alkermes, Inc.
Christi L. Shaw, MBA
Chief Executive Officer, Kite, a Gilead Company
Bill Sibold, MBA
Executive Vice President, Genzyme Corporation, A Sanofi Company
Helen Torley, MRCP
President & CEO, Halozyme Therapeutics, Inc.

Section Governing Boards

Emerging Companies Section Governing Board

Ted W. Love, MD Chair
Chief Executive Officer, Global Blood Therapeutics
Bonnie Anderson
Chairman & Chief Executive Officer, Veracyte, Inc.
Martin Babler
President & CEO, Principia Biopharma
Laura A. Berezin
Partner, Cooley LLP
Jeffrey L. Cleland, PhD
Chairman, CEO & President, Ashvattha Therapeutics, Inc.
Ron Cohen, MD
Founder, President & CEO, Acorda Therapeutics, Inc.
John F. Crowley, JD, MBA
Chairman & CEO, Amicus Therapeutics, Inc.
Bassil I. Dahiyat, PhD
President & CEO, Director, Xencor, Inc
Douglas A. Doerfler
President & CEO, MaxCyte, Inc
Mark Drozdowski
Partner - Pharmaceuticals National Audit Leader, KPMG LLP
Alexandria Forbes, PhD
President & CEO, MeiraGTx
Cedric Francois, MD, PhD
Co-Founder & CEO/President, Apellis Pharmaceuticals, Inc
Kevin C. Gorman, PhD
Chief Executive Officer, Neurocrine Biosciences, Inc
Justin Gover
Chief Executive Officer, GW Pharmaceuticals Plc
Paul J. Hastings
President & CEO, Nkarta Therapeutics, Inc.
Russell H. Herndon
President & CEO, Hydra Biosciences, Inc
Alexander Karnal
Partner, Deerfield Management Company LP
Jeff B. Kindler
Chief Executive Officer, Centrexion Therapeutics
Rachel K. King
Founder & CEO, GlycoMimetics, Inc.
Scott Koenig, MD, PhD
President & CEO, MacroGenics, Inc
Nick Leschly
President & CEO, bluebird bio
Jeremy M. Levin, DPhil, MB BChir
Chairman & CEO, Ovid Therapeutics Inc.
Sandy Macrae, PhD
President & CEO, Sangamo Therapeutics, Inc.
John Maraganore, PhD
Chief Executive Officer, Alnylam Pharmaceuticals, Inc.
Jeffrey D. Marrazzo
Co-Founder & CEO, Spark Therapeutics
Sharon Mates, PhD
Founder, Chairman & CEO, Intra-Cellular Therapies, Inc.
Kenneth I. Moch
President & CEO, Cognition Therapeutics
Bob J. More
Managing Director, Alta Partners
Michael Narachi, MBA, MS
President & CEO, CODA Biotherapeutics
Amir Nashat
Managing Partner, Polaris Ventures
William J. Newell, JD
Chief Executive Officer, Sutro Biopharma, Inc.
Julia Owens, PhD
President & CEO, Millendo Therapeutics Inc.
Adelene Q. Perkins, MBA
Chair & Chief Executive Officer, Infinity Pharmaceuticals, Inc.
Mark Pruzanski, MD
President, CEO & Director, Intercept Pharmaceuticals, Inc.
Michael G. Raab
Chief Executive Officer, Ardelyx Inc.
James Sapirstein, MBA, RPh
Executive Chairman, Marizyme Inc.
George A. Scangos, PhD
Chief Executive Officer & Director, VIR Biotechnology, Inc.
Nancy Simonian, MD
Chief Executive Officer & President, Syros Pharmaceuticals
Erika Smith, MBA
Chief Executive Officer, ReNetX Bio
Gil Van Bokkelen, PhD
Founder, Chairman & CEO, Athersys, Inc.
Timothy P. Walbert
Chairman, President & CEO, Horizon Therapeutics plc
Sue Washer, MBA
President & CEO, Applied Genetic Technologies Corporation (AGTC)
Thomas G. Wiggans, MBA
Founder, CEO & Chairman of Board of Directors, Dermira, Inc.
Robert J. Wills, PhD
Chairman, CymaBay Therapeutics
Bradford A. Zakes, MBA
President & Chief Executive Officer, Cerevast Therapeutics, Inc.

Food & Ag Section Governing Board

Philip W. Miller, PhD Chair
Sr. Vice President, Agricultural Global Government Relations, Regulatory Policy, Bayer CropScience, Inc.
Scott Holmstrom
Vice President, Global Product Development, Elanco
Mark Platt
President & CEO, Recombinetics, Inc
Eddie J. Sullivan, PhD
President & CEO, SAB Biotherapeutics
Karsten Temme, PhD
CEO & Co-Founder, Pivot Bio, Inc.
Rick Turner
Senior Vice President, Seeds & Traits, BASF Corporation
Sylvia Wulf
Chief Executive Officer, AquaBounty Technologies, Inc.

Health Section Governing Board

Jeremy M. Levin, DPhil, MB BChir Chair
Chairman & CEO, Ovid Therapeutics Inc.
Paul J. Hastings Vice Chair
President & CEO, Nkarta Therapeutics, Inc.
John Maraganore, PhD Immediate Past Chair
Chief Executive Officer, Alnylam Pharmaceuticals, Inc.
Helen Torley, MRCP Secretary
President & CEO, Halozyme Therapeutics, Inc.
Steve Albers
Corporate Vice President, Market Access and Public Affairs, Novo Nordisk
Bonnie Anderson
Chairman & Chief Executive Officer, Veracyte, Inc.
Stuart A. Arbuckle
Executive Vice President and Chief Commercial Office, Vertex Pharmaceuticals Incorporated
Martin Babler
President & CEO, Principia Biopharma
Jean-Jacques Bienaime
Chairman & CEO, BioMarin Pharmaceutical, Inc.
Christophe Bourdon
General Manager, Amgen Inc.
Jeffrey L. Cleland, PhD
Chairman, CEO & President, Ashvattha Therapeutics, Inc.
Ron Cohen, MD
Founder, President & CEO, Acorda Therapeutics, Inc.
Terrie Curran
President, Inflammation and Immunology, Celgene Corporation
Douglas A. Doerfler
President & CEO, MaxCyte, Inc
Mark Enyedy
President & CEO, ImmunoGen, Inc.
Barry Flannelly, MBA, PharmD
Executive Vice President & General Manager US, Incyte Corporation
Alexandria Forbes, PhD
President & CEO, MeiraGTx
Cedric Francois, MD, PhD
Co-Founder & CEO/President, Apellis Pharmaceuticals, Inc
Julie L. Gerberding, MD, MPH
Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, Merck
Chirfi Guindo
EVP, Global Product Strategy & Commercialization, Biogen
Sebastian Guth
President of Pharmaceuticals, Americas Region, Bayer Corporation
Alexander Hardy
Chief Executive Officer, Genentech, A Member of the Roche Group
Christopher P. Healey
President, Corporate Affairs and Global Patient Relations, Grifols
Rachel K. King
Founder & CEO, GlycoMimetics, Inc.
Scott Koenig, MD, PhD
President & CEO, MacroGenics, Inc
Joseph LaRosa, Esq
Executive Vice President, General Counsel and Secretary, Regeneron Pharmaceuticals, Inc.
John Lepore, MD
SVP, R&D Pipeline, GlaxoSmithKline
Nick Leschly
President & CEO, bluebird bio
Liz Lewis
Chief Counsel, Specialty BUs & R&D; Head, Patient Advocacy, Oncology BU, Takeda Pharmaceutical Company Limited
Ted W. Love, MD
Chief Executive Officer, Global Blood Therapeutics
Sandy Macrae, PhD
President & CEO, Sangamo Therapeutics, Inc.
Paige Mahaney, PhD
Global Head of Biotherapeutics Discovery Research and Discovery Research Site Head, Boehringer Ingelheim
Ameet Mallik
Executive Vice President and Head, US Novartis Oncology, Novartis
Jeffrey D. Marrazzo
Co-Founder & CEO, Spark Therapeutics
Sharon Mates, PhD
Founder, Chairman & CEO, Intra-Cellular Therapies, Inc.
Kenneth I. Moch
President & CEO, Cognition Therapeutics
Michael M. Morrissey, PhD
President & CEO, Exelixis, Inc.
Michael Narachi, MBA, MS
President & CEO, CODA Biotherapeutics
William J. Newell, JD
Chief Executive Officer, Sutro Biopharma, Inc.
David Nicholson, PhD
EVP & Chief R&D Officer, Allergan
Julia Owens, PhD
President & CEO, Millendo Therapeutics Inc.
John Oyler
CEO & Co-Founder, BeiGene, Ltd.
Richard A. Paulson, MBA
EVP & CEO of Ipsen NA, Ipsen Biopharmaceuticals, Inc.
Adelene Q. Perkins, MBA
Chair & Chief Executive Officer, Infinity Pharmaceuticals, Inc.
Richard Pops
Chairman & CEO, Alkermes, Inc.
Shaji Procida
President & COO, Eisai, Inc
Mark Pruzanski, MD
President, CEO & Director, Intercept Pharmaceuticals, Inc.
Michael G. Raab
Chief Executive Officer, Ardelyx Inc.
Howard W. Robin
President & CEO, Nektar Therapeutics, Inc.
Michael Ryan, PharmD
SVP, Worldwide Value, Access, Policy & Health Economics & Outcomes Research, Bristol-Myers Squibb Company
Bill Sibold, MBA
Executive Vice President, Genzyme Corporation, A Sanofi Company
Nancy Simonian, MD
Chief Executive Officer & President, Syros Pharmaceuticals
Elaine Sorg
President, U.S. Immunology and Patient Services, AbbVie Inc.
Jennifer Taubert
Worldwide Chairman of Pharmaceuticals, Johnson & Johnson
Mark Timney
Chief Executive Officer, The Medicines Company
Mark Trudeau
President & CEO, Mallinckrodt Pharmaceuticals
Gil Van Bokkelen, PhD
Founder, Chairman & CEO, Athersys, Inc.
Charl Van Zyl
Chief Operating Officer, UCB SA
Timothy P. Walbert
Chairman, President & CEO, Horizon Therapeutics plc
Sue Washer, MBA
President & CEO, Applied Genetic Technologies Corporation (AGTC)
Anne White
Senior Vice President and President of Lilly Oncology, Eli Lilly and Company
Thomas G. Wiggans, MBA
Founder, CEO & Chairman of Board of Directors, Dermira, Inc.
Rick E. Winningham
Chief Executive Officer, Theravance Biopharma US, Inc.
John Young
Chief Business Officer, Pfizer Inc.
Bernhardt Zeiher, MD
Chief Medical Officer, Astellas Pharma US, Inc.

Industrial & Environmental Section Governing Board

Hugh Welsh, JD Chair
General Counsel, Secretary & President, DSM North America
Jill Zullo, PhD Vice Chair
Vice President, Bioindustrials NA, Cargill, Inc
Doug Berven
Vice President, Corporate Affairs, Poet, LLC
Patrick Gruber, MBA, PhD
Chief Executive Officer, Gevo, Inc
Jennifer Holmgren, MBA, PhD
Chief Executive Officer, LanzaTech
David Kettner
President, Virent, Inc
John G. Melo
Chief Executive Officer, Amyris, Inc.
Anna Rath, JD
President & CEO, Vestaron Corporation
Christophe Schilling, PhD
Chief Executive Officer & Co-Founder, Genomatica, Inc
Diane Shanahan
Director, Regulatory Affairs, BASF Enzymes LLC
Chris Standlee, JD
Vice President, Legal Affairs, ICM, Inc
Brian Thome
President & Chief Executive Officer, Edeniq Inc.
Oliver Walker
Chief Executive Officer, Evolva SA
Robert F. Walsh
Senior Vice President, Energy & Fine Chemicals Platforms, Intrexon Corporation
Roger Wyse, PhD
Founder, Managing Partner, Spruce Capital Partners